慢性心力衰竭的药物治疗
1King's College Hospital NHS Foundation Trust, London, UK aamir.shamsi@nhs.net.
Drug and therapeutics bulletin
|September 4, 2025
概括
本综述详细介绍了治疗慢性心力衰竭的四大主要药物类别. 在HFrEF患者的最佳结果取决于早期诊断和个性化治疗这些药物.
科学领域:
- 心脏病学
- 药理学
- 内部医学
背景情况:
- 心力衰竭是一种发病率和死亡率高的渐进性综合征.
- 肺炎对医疗保健资源产生重大影响,占英国NHS紧急住院病例的5%.
- 慢性心力衰竭与减少喷射分数 (HFrEF) 影响大约60% 的心力衰竭患者.
研究的目的:
- 审查慢性HFrEF的药理治疗.
- 讨论HFrEF患者管理中的关键考虑因素.
- 强调药物管理,并发症解决和生活方式修改的重要性.
主要方法:
- 专注于HFrEF的药理治疗策略.
- 讨论四个关键药物类别:ACE抑制剂/ARNI,β抑制剂,MRA和SGLT2i.
- 强调这些药物类别的协同效应.
主要成果:
- HFrEF治疗的四个支柱包括ACE抑制剂/ARNI,β- 阻断剂,MRA和SGLT2i.
- 个性化治疗和早期诊断对于患者的结果至关重要.
- 与这些药物类别的联合治疗可以改善患者的治疗结果.
结论:
- 慢性HFrEF的有效管理依赖于四个关键药物类别的组合.
- 这些药物的个性化治疗计划至关重要.
- 综合护理包括药物管理,解决并发症,促进生活方式改变以改善HFrEF结果.
相关概念视频
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure IV: Classification and Diagnostic Evaluation
31
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
31
Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434


